Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387. doi:10.1136/gutjnl-2014-30812425320104
   PubMed Web of Science ®Google Scholar
• Liang H, Fan J-H, Qiao Y-L. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33–41. doi:10.20892/j.issn.2095-3941.2016.009328443201
   PubMed Web of Science ®Google Scholar
• Herskovic A, Russell W, Liptay M, et al. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23(5):1095–1103. doi:10.1093/annonc/mdr43322003242
   PubMed Web of Science ®Google Scholar
• Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–692. doi:10.1016/S1470-2045(11)70142-521684205
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa111208822646630
   PubMed Web of Science ®Google Scholar
• Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234. doi:10.1016/S1470-2045(07)70039-617329193
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–1092. doi:10.1200/JCO.2007.12.959318309943
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJB, Hulshof MCCM. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098. doi:10.1016/S1470-2045(15)00040-626254683
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Thomas JM, Burmeister EA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–360. doi:10.1016/j.ejca.2010.09.00921084184
   PubMed Web of Science ®Google Scholar
• Klevebro F, Alexandersson von Döbeln G, Wang N. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–667. doi:10.1093/annonc/mdw01026782957
   PubMed Web of Science ®Google Scholar
• Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–2803. doi:10.1200/JCO.2018.79.148330089078
   PubMed Web of Science ®Google Scholar
• Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32(23):2416–2422. doi:10.1200/JCO.2013.53.653224982463
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–5067. doi:10.1200/JCO.2009.22.208319770374
   PubMed Web of Science ®Google Scholar
• Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. doi:10.1245/s10434-011-2049-921879261
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren Z, Yuan L, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res. 2016;6(10):2345–2350.27822423
   PubMed Web of Science ®Google Scholar
• Zhao Y, Dai Z, Min W, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J Thorac Oncol. 2015;10(9):1349–1356. doi:10.1097/JTO.000000000000061226287319
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the Esophagus and Esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36–42. doi:10.1016/j.jtho.2016.10.01627810391
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Protocol development. CTEP [Internet]. [cited November 26, 2020]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 218, 2021.
   Google Scholar
• Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518–526.1598671
   PubMed Web of Science ®Google Scholar
• von Döbeln GA, Klevebro F, Jacobsen AB. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus. 2019;32(2). doi:10.1093/dote/doy078
   PubMed Web of Science ®Google Scholar
• Sun HB, Xing WQ, Liu XB. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer. 2020;20(1):303. doi:10.1186/s12885-020-06824-232293362
   PubMed Web of Science ®Google Scholar
• Tang H, Tan L, Shen Y, et al. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596). BMC Cancer. 2017;17:450. doi:10.1186/s12885-017-3446-728659128
   PubMed Web of Science ®Google Scholar
• Jun L, Zhigang L, Yang Y, et al. A prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer(TESCC) wth multi-station lymph node metastases (NICE study): preliminary results. Ann Oncol. 2020;31(S6):S1292. doi:10.1016/j.annonc.2020.10.148
   Web of Science ®Google Scholar
• Zhang G, Hu Y, Yang B, et al. A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma(ESCC). Ann Oncol. 2020;31(S4):S722. doi:10.1016/j.annonc.2020.08.1178
   Web of Science ®Google Scholar